Physician profile

James Bingham

Internal Medicine · Cincinnati, OH

NPI 1063413821

$1,536.95

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $337.49 2019-2021
Novartis Pharmaceuticals Corporation $229.07 2019-2022
Sanofi-Aventis U.S. LLC $172.54 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $107.09 2019-2022
Teva Pharmaceuticals USA, INC. $90.94 2019-2022
Amarin Pharma, INC. $73.30 2019-2022
Astrazeneca Pharmaceuticals Lp $70.08 2019-2021
Lilly USA, LLC $67.26 2019-2022
Pfizer INC. $58.76 2019-2020
Novo Nordisk INC $56.23 2019-2022
Janssen Pharmaceuticals, INC $55.66 2019-2021
Kowa Pharmaceuticals America, INC. $42.95 2019-2021
Biohaven Pharmaceutical Holding Company Ltd. $37.54 2022
Abbvie INC. $30.13 2021-2022
Merck Sharp & Dohme LLC $23.34 2019-2020
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Abbott Laboratories $17.08 2019
Hikma Pharmaceuticals USA $16.40 2019
Esperion Therapeutics, INC. $15.28 2021
Dexcom, INC. $12.91 2022
Sanofi Pasteur INC. $11.71 2019
Shire North American Group INC $11.19 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Bingham

$1,536.95

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/138300/james-bingham

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.